Michigan Hydroxychloroquine Study Shows Significant Benefit for Treatment

MICHIGAN – A Henry Ford Health System study shows the controversial anti-malaria drug hydroxychloroquine helps lower the death rate of COVID-19 patients, the Detroit-based health system said Thursday.

Officials with the Michigan health system said the study found the drug “significantly” decreased the death rate of patients involved in the analysis.

The study analyzed 2,541 patients hospitalized among the system’s six hospitals between March 10 and May 2 and found 13% of those treated with hydroxychloroquine died while 26% of those who did not receive the drug died.

Among all patients in the study, there was an overall in-hospital mortality rate of 18%, and many who died had underlying conditions that put them at greater risk, according to Henry Ford Health System.

Speaking to reporters at the White House, Peter Navarro, drew attention to the Michigan study as well as another in New York.  Navarro pointed out that media opposition to the treatment has likely resulted in unnecessary death.

NAVARRO – “A new study came out from Henry Ford hospital system that shows that if we take the medicine hydroxychloroquine In early treatment, we can observe a more than 50% reduction in mortality, without any adverse effects.”

“Now what, what, practically, that means is that if we had been using hydroxychloroquine at the very beginning, we could have saved 10s of thousands of lives already. And moving forward If hydroxychloroquine is used under the advice of the physician in early treatment, this study suggests that we could save hundreds of thousands of American lives over time and perhaps millions worldwide.”

“And the same day that that came out, a similar study came out from Mount Sinai Hospital system, which had a similar conclusion that hydroxychloroquine basically lowers the mortality rate.”

For the rest of this story go to  Michigan Hydroxychloroquine Study Shows Significant Benefit for Treatment – Media Shocked… — The Last Refuge